-
-
-
-
-
-
-
Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates
-
-
-
-
-
-
-
Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator
-
-
-
-
-
-
-
Orchestra BioMed Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates
-
-
-
-
-
-
-
Ligand to Report Second Quarter 2025 Financial Results on August 7, 2025
-
-
-
-
-
-
-
Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics
-
-
-
-
-
-
-
Ligand Pharma (LGND) Tops Q3 EPS by 50c ; Offers Guidance
-
-
-
-
-
-
-
 Ligand to Acquire APEIRON Biologics AG for $100 Million
-
1,208,014 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

